TET3

Methylcytosine dioxygenase TET3 · O43151 · TET3 on Sugi Atlas →

10,245 patent compounds predicted against TET3, 7,154 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL167151	0.47	4/20
SCHEMBL348394	0.43	3/20
SCHEMBL301027	0.64	2/20
SCHEMBL458815	0.64	2/20
SCHEMBL654813	0.59	2/20
SCHEMBL126063	0.56	2/20
Malic Acid (SCHEMBL89131)	0.55	2/20
Malic Acid (SCHEMBL95333)	0.52	2/20
Malic Acid (SCHEMBL118307)	0.52	2/20
Malic Acid (SCHEMBL121545)	0.52	2/20
Malic Acid (SCHEMBL123090)	0.52	2/20
Malic Acid (SCHEMBL162063)	0.52	2/20
Malic Acid (SCHEMBL162119)	0.52	2/20
Malic Acid (SCHEMBL163100)	0.52	2/20
Malic Acid (SCHEMBL215609)	0.52	2/20
Malic Acid (SCHEMBL217490)	0.52	2/20
Malic Acid (SCHEMBL220041)	0.52	2/20
Malic Acid (SCHEMBL631099)	0.52	2/20
Malic Acid (SCHEMBL631100)	0.52	2/20
Malic Acid (SCHEMBL637799)	0.52	2/20

Clinical trials — most relevant to TET3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	PHASE3	UNKNOWN
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations	PHASE2	SUSPENDED
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS	PHASE2	UNKNOWN
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker	PHASE2	NOT_YET_RECRUITING
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
FdCyd and THU for Advanced Solid Tumors	PHASE1	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity	nan	UNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test	nan	UNKNOWN
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies	nan	UNKNOWN
Genetic Aspects of Vaginal Aging	nan	COMPLETED
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer	nan	RECRUITING
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL	nan	RECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
Exploratory Study of Rectal Mucus for Diagnosing Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TET3 binder may also engage these)

Protein	Name	Similarity
Q8BG87	—	1.000	Q8BG87 →
O08696	—	1.000	O08696 →
P21999	—	1.000	P21999 →
Q90932	—	1.000	Q90932 →
GLI1	Zinc finger protein GLI1	0.999	landscape →
Q63449	—	0.999	Q63449 →
Q5VV67	—	0.998	Q5VV67 →
Q61575	—	0.998	Q61575 →
Q80U22	—	0.998	Q80U22 →
Q3B8N5	—	0.998	Q3B8N5 →
Q9EPW2	—	0.998	Q9EPW2 →
KDM3B	Lysine-specific demethylase 3B	0.998	landscape →
Q9D1Z2	—	0.997	Q9D1Z2 →
A6X8Z5	—	0.997	A6X8Z5 →
P10244	—	0.997	P10244 →
Q3UHR0	—	0.997	Q3UHR0 →
Q5TGY3	—	0.997	Q5TGY3 →
Q00175	—	0.997	Q00175 →
Q8BZ32	—	0.997	Q8BZ32 →
Q6NZN1	—	0.997	Q6NZN1 →
P08651	—	0.997	P08651 →
Q9H4Z2	—	0.997	Q9H4Z2 →
P47806	—	0.997	P47806 →
Q00587	—	0.997	Q00587 →
Q5NCY0	—	0.997	Q5NCY0 →
Q9ER75	—	0.997	Q9ER75 →
Q3V0A6	—	0.996	Q3V0A6 →
Q6P1W5	—	0.996	Q6P1W5 →
Q9HCH0	—	0.996	Q9HCH0 →
Q99P96	—	0.996	Q99P96 →